Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: Radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Bone Marrow
  • Bone Marrow Diseases
  • Maximum Tolerated Dose
  • Prostate-Specific Antigen
  • Radiation Injuries
  • Yttrium Radioisotopes

abstract

  • In patients with prostate cancer, myelotoxicity after treatment with (177)Lu-J591 can be predicted on the basis of the amount of radioactive dose administered or the BMrad. The lack of correlation between myelotoxicity and (90)Y-J591 BMrad may be due to several factors. (90)Y-J591 may be less stable in vivo and, as a result, higher amounts of free (90)Y may be localized in the bone. In addition, the cross-fire effect of high-energy beta(-)-particles within the bone and the marrow may deliver radiation dose nonuniformly within the marrow.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 15872360

Additional Document Info

start page

  • 850

end page

  • 8

volume

  • 46

number

  • 5